Shares of Biocept Inc., which provides liquid biopsy tests for cancer
patients, rose 12% to 40 cents after hours as the company said it will
conduct Covid-19 testing.
Biocept said it has verified a molecular diagnostic test, and plans
to begin accepting physician-ordered testing requests for processing
beginning April 15.
Biocept’s lab will use Thermo Fisher Scientific Inc.’s TaqPath platform and kit.
https://www.marketscreener.com/BIOCEPT-INC-44644720/news/Biocept-Shares-Up-on-Planned-Start-of-Covid-19-Testing-30394798/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.